Quest Licenses Septin 9 Marker from Epigenomics | GenomeWeb

Epigenomics has licensed to Quest Diagnostics its DNA-methylation biomarker Septin 9, which the company will use to develop a homebrew colorectal cancer diagnostic.

Quest is the first commercial laboratory in the US to obtain a non-exclusive license to the Septin 9 biomarker from Epigenomics to manufacture a laboratory-developed colo-rectal cancer test. Epi-genomics granted Quest exclusivity for an undisclosed period for being a "first-mover" in the US, in exchange for upfront and milestone payments, as well as royalties on sales of the test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.